ClinicalTrials.gg
Active, not recruitingNCT05438407Updated May 6, 2026

Pediatric Patients Aged 4 to 11 Years With APDS

A Phase 3 interventional study of Leniolisib in APDS, sponsored by Pharming Technologies B.V.. Active, not recruiting at 7 sites in 3 countries. Open to participants aged 4 Years to 11 Years. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by Pharming Technologies B.V. (part of Pharming Group N.V.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
4 Years to 11 Years
Sex
All
01

Study summary

This is a 2-part, prospective, open-label, single arm, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and efficacy of leniolisib in at least 15 pediatric patients (aged 4 to 11 years) with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS).

Read the detailed description

Part I will consist of a 12-week period to assess the safety and efficacy of treatment with leniolisib. Part II will consist of a 1-year, long-term, safety follow-up extension with a possible interim analysis.

The leniolisib doses to be used in study were selected based on safety, tolerability, PK, and PDx data from the adult Phase 2/3 study, as well as PK modeling data. In both parts of the study, leniolisib will be administered orally based on weight.

02

Conditions studied

  • APDS
03

In context

Lead sponsor

Pharming Technologies B.V. is the lead sponsor of 22 studies on the registry; 3 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
4 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Diagnosis and main criteria for inclusion and exclusion:

Patients must satisfy all of the following criteria at the screening visit unless otherwise stated:

  1. Patient is male or female and between the age of 4 to 11 years old at the time of the first study procedure.
  2. Patient weighs ≥13 kg and \<45 kg at baseline.
  3. Patient has a confirmed PI3Kδ genetic mutation of either the PIK3CD (APDS1) or PIK3R1 (APDS2) gene.
  4. Patient has at least 1 measurable nodal lesion on magnetic resonance imaging/low-dose computed tomography within 6 months of screening.
  5. Patient has nodal or extranodal lymphoproliferation and clinical findings consistent with APDS (eg, a history of repeated oto-sino-pulmonary infections and/or organ dysfunction consistent with APDS).
  6. Patient has the ability to ingest unaltered study-related medications without difficulty in the investigator's opinion.
  7. At screening, vital signs (systolic blood pressure [BP], diastolic BP, and pulse rate) will be assessed in the sitting position after the patient has been at rest for at least 3 minutes. Patient's sitting vital signs should be within the following ranges:

    • Systolic BP: Less than the 95th percentile adjusted for sex, age, and height percentile.
    • Diastolic BP: Less than the 95th percentile adjusted for sex, age, and height percentile.
    • Heart rate (HR):

      i) Age 4 to \<10 years: 60 to 140 bpm ii) Age ≥10 years: 50 to 100 bpm

  8. Institutional review board-/independent ethics committee-approved written /assent and privacy language as per national and local regulations must be obtained from the patient and parent/legal guardian prior to any study-related procedures.
  9. Patient parent/legal guardian is willing and able to complete the informed consent/assent process and comply with study procedures and visit schedule.
  10. Patient parent/legal guardian agrees patient will not participate in any other interventional study while enrolled in this study.
  11. Female patients should be of non- at screening (should not have reached menarche). Male patients with partners of childbearing potential should be willing to use a highly effective method of for at least 30 days after the last study procedure if at risk of pregnancy.
  12. Female patient and parent/legal guardian must agree to the following if menses develops after screening, up to 30 days after the last study procedure:

    • True sexual abstinence defined as refraining from heterosexual activity during the entire period of the study through 6 months post-study or
    • Using a highly effective method of contraception for at least 30 days after the last study procedure if at risk of pregnancy.

Patients will be excluded from the study if they satisfy any of the following criteria at the screening visit unless otherwise stated:

  1. Patient has previous or concurrent use of medication such as:

    a. An mTOR inhibitor (eg, sirolimus, rapamycin, everolimus) or a PI3Kδ inhibitor (selective or non-selective PI3K inhibitors) within 6 weeks prior to first dose.

    i. Short-term use for up to a total of 5 days is allowed but only up to 1 month prior to enrollment in the study.

    b. B cell depleters (eg, rituximab) within 6 months prior to first dose of study medication.

    i. If patient has received prior treatment with a B cell depleter, absolute B lymphocyte counts in the blood must have regained normal values.

    c. Belimumab or cyclophosphamide within 6 months prior to first dose of study medication.

    d. Cyclosporine A, mycophenolate, 6-mercaptopurine, azathioprine, or methotrexate within 3 months prior to first dose of study medication.

    e. Systemic above a dose equivalent to either ≥2 mg/kg of body weight or ≥20 mg/day of prednisone/prednisolone or equivalent.

    f. Other immunosuppressive medication where effects are expected to persist at start of dosing of study medication.

  2. Patient has a history or current diagnosis of (ECG) abnormalities indicating significant risk of safety for patients participating in the study such as:

    1. History of familial long syndrome or known family history of Torsades de Pointes.
    2. Concomitant cardiac arrhythmias (eg, sustained ventricular tachycardia, and clinically significant second or third degree atrioventricular block without a pacemaker).
    3. Resting QTc (Fridericia preferred, but Bazett acceptable) >460 msec if the measurement is confirmed with an additional ECG repeated as soon as possible.
    4. Concomitant use of agents known to prolong the QT interval unless it can be permanently discontinued for the duration of the study.
  3. Patient is currently using a medication known to be a strong inhibitor or moderate or strong inducer of isoenzyme cytochrome P450 (CYP)3A, if treatment cannot be discontinued or switched to a different medication prior to starting study treatment.
  4. Patient is currently using medications that are metabolized by isoenzyme CYP1A2 and have a narrow therapeutic index (drugs whose exposure-response indicates that increases in their exposure levels by the concomitant use of potent inhibitors may lead to serious safety concerns [eg, Torsades de Pointes]).
  5. Patient had been administered (this includes any attenuated live vaccines) starting from 6 weeks before the anticipated first study drug administration, during the study, and up to 7 days after the last dose of leniolisib.
  6. Patient has clinically significant abnormalities in hematology or clinical chemistry (blood chemistry or urinalysis) parameters as determined by the investigator or medical monitor.
  7. Patient has liver disease or liver injury as indicated by clinically significant abnormal liver function tests ( and aspartate aminotransferase >2.5 times ), history of renal injury/renal disease (eg, renal trauma, glomerulonephritis, or one kidney only), or presence of impaired renal function as indicated by a serum creatinine level >1.5 mg/dL (133 μmol/L).
  8. Patient has moderate or severe hepatic impairment ( Class B or C).
  9. Patient is receiving concurrent treatment with another therapy or use of another investigational therapy less than 4 weeks from the first study procedure.
  10. Patient has active (eg, hepatitis B surface antigen reactive) or active (eg, hepatitis C virus RNA [qualitative] is detected) at screening.
  11. Patient has (HIV) infection (HIV 1 or 2) at screening.
  12. Patient has a positive coronavirus disease 19 result (polymerase chain reaction or antigen) within 1 week prior to first dose. The patient can be rescreened after a subsequent negative result.
  13. Patient has a history of (except lymphoma) within 3 years before the first study procedure or has evidence of residual disease from a previously diagnosed malignancy.
  14. Patient has a previous diagnosis of lymphoma that has been treated with chemotherapy, radiotherapy, or transplant within 1 year of the first study procedure or is anticipated to require lymphoma treatment within 6 months of the first study procedure.
  15. Patient has a history of uncontrolled diabetes mellitus within 3 months of the first study procedure.
  16. Patient has had major surgery requiring hospitalization or radiotherapy within 4 weeks prior to the first study procedure.
  17. Patient has uncontrolled chronic or recurrent infectious disease (with the exception of those that are considered to be characteristic of APDS) or evidence of tuberculosis infection as defined by a positive Mantoux tuberculin skin test at screening. If presence of latent tuberculosis is established, then treatment according to local country guidelines must have been completed before patients can be considered for enrollment.
  18. Patient has a known allergy or history of to study defined medications or any ingredients of the medications, including the following common :

    • Lactose monohydrate
    • Microcrystalline cellulose
    • Sodium starch glycolate (Type A)
    • Hypromellose
    • Magnesium stearate
    • Colloidal silicon dioxide
    • Opadry yellow
  19. Patient has a planned or expected major surgical procedure.
  20. Patient or parent/legal guardian is unable or unwilling to comply with study procedures or is unable to travel for repeat visits.
  21. Patient or parent/legal guardian is unwilling to keep study results/observations confidential or to refrain from posting confidential study results/observations on social media sites.
  22. Patient or parent/legal guardian refuses to sign consent/assent form.
  23. Patient has other underlying medical condition that, in the opinion of the investigator, would impair the ability of the patient to receive or tolerate the planned procedures or follow-up.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Leniolisib

    Leniolisib - Film Coated Tablets Leniolisib tablets in 10 and 30 mg strengths administered orally BID by body weight for 12 weeks for Part I and for 1 year for Part II.

    Drug: Leniolisib

Interventions

  • The doses selected range from 20 to 70 mg BID (resulting in total daily doses ranging from 40 to 140 mg per day) based on weight. The doses will be administered as (a combination of) 10 mg and 30 mg tablets

06

What researchers measure

Primary outcomes

  1. Part I & II: Number of Participants with Treatment-emergent adverse events (TEAEs), Serious Adverse Events (SAEs) , and Adverse Events (AEs)

    Number of Participants with TEAEs, SAEs, and AEs leading to discontinuation of study drug

    Time frame: From baseline to end of 12 weeks, & From baseline to through study completion, an average of 1 year, plus 30 days

  2. Part I & II: Change from baseline in clinical laboratory test results

    Number of Participants with change in clinical laboratory test results (hematology, blood chemistry, urinalysis)

    Time frame: From baseline to end of 12 weeks, & From baseline to through study completion, an average of 1 year

  3. Part I & II: Change from baseline in vital signs

    Number of Participants with change in vital signs

    Time frame: From baseline to end of 12 weeks, & From baseline to through study completion, an average of 1 year

  4. Part I & II: Change from baseline in physical examination findings

    Number of Participants with change in physical examination findings

    Time frame: From baseline to end of 12 weeks, & From baseline to through study completion, an average of 1 year

  5. Part I & II: Change from baseline in electrocardiograms (ECGs)

    Number of Participants with change in electrocardiograms (ECGs)

    Time frame: From baseline to end of 12 weeks, & From baseline to through study completion, an average of 1 year, plus 30 Days

  6. Part I & II: Change from baseline in growth and physical development

    Number of Participants with change in growth and physical development

    Time frame: From baseline to end of 12 weeks, & From baseline to through study completion, an average of 1 year

  7. Part I & II: Reduction in lymphoproliferation as measured by MRI or low-dose CT

    For the assessment of the impact of leniolisib on lymphoproliferation, patients will be scanned in an MRI or a CT scanner as based on clinical practice and local regulation. Index lesions will be selected from measurable nodal and extra nodal lesions as per the Cheson methodology. The same imaging modality will be used throughout the study for the same patient. Patients will be assessed by MRI, or in sites where local practice and local authorities/IECs/IRBs approve CT scans for research purposes using a low-dose CT scan.

    Time frame: Part I: Baseline and Day 85 Part II: at Day 252, through study completion, an average of 1 year

  8. Part I: A Percentage of Inhibition of Unstimulated and Stimulated pAkt Levels in B Cells

    The PDx effect of leniolisib will be assessed using ex vivo stimulated and unstimulated phosphorylation of Akt in B cells. Akt is a direct downstream target of activated PI3Kδ. Determination of the percentage (%) of CD20+ pAkt positive cells after ex vivo stimulation of whole blood is performed by flow cytometry analysis. Unstimulated cells will serve as controls.

    Time frame: Part I: Baseline, Days 29, 57 and 85

Secondary outcomes

  1. Part I: To evaluate changes in Pharmacokinetic (PK) profile/parameters

    To evaluate changes in Cmax, Tmax AUC, T1/2

    Time frame: From baseline to end of 12 weeks of treatment]

  2. Part I: To evaluate changes in Pharmacodynamic (PD) profile/parameters

    To evaluate changes in pAkt and Serum Immunoglobulin Profile

    Time frame: From baseline to end of 12 weeks of treatment]

  3. Part I: To assess the total drug exposure (AUC) of leniolisib in pediatric patients (aged 4 to 11 years) with APDS

    Population pharmacokinetics (popPK) model that describes the appropriate covariates (eg, body weight and age) that influence leniolisib PK in pediatric patients.

    Time frame: From baseline to end of 12 weeks of treatment

  4. Part I: To assess the maximum concentration (Cmax) of leniolisib in pediatric patients (aged 4 to 11 years) with APDS

    Population pharmacokinetics (popPK) model that describes the appropriate covariates (eg, body weight and age) that influence leniolisib PK in pediatric patients.

    Time frame: From baseline to end of 12 weeks of treatment

  5. Part I: To assess the time to maximum concentration (Tmax) of leniolisib in pediatric patients (aged 4 to 11 years) with APDS

    Population pharmacokinetics (popPK) model that describes the appropriate covariates (eg, body weight and age) that influence leniolisib PK in pediatric patients.

    Time frame: From baseline to end of 12 weeks of treatment

  6. Part II: Changes from baseline for Reduction in lymphadenopathy as measured by MRI or low-dose CT

    Parameters for reduction in lymphadenopathy as a key secondary endpoint of Part II may include 3D volume of index and measurable non-index lesions selected as per the Cheson methodology. Summary statistics will be provided by visit. Arithmetic mean with SD of absolute values and change from baseline values may be plotted across time.

    Time frame: Day 85 to through study completion, an average of 1 year

  7. Part II: Changes from baseline for Reduction in lymphadenopathy as measured by MRI or low-dose CT

    Parameters for reduction in 3D volume and bi-dimensional or 3D sizes of spleen, where appropriate. Summary statistics will be provided by visit. Arithmetic mean with SD of absolute values and change from baseline values may be plotted across time.

    Time frame: Day 85 to through study completion, an average of 1 year

  8. Part II: Changes from baseline for Reduction in lymphadenopathy as measured by MRI or low-dose CT

    Parameters for reduction in 3D volume and bi-dimensional or 3D sizes of liver, where appropriate. Summary statistics will be provided by visit. Arithmetic mean with SD of absolute values and change from baseline values may be plotted across time.

    Time frame: Day 85 to through study completion, an average of 1 year

  9. Part I and II: Key secondary efficacy outcomes for Part I include incidence of infections and use of antibiotics.

    The number and percentage of patients with infections, and the total number of infections will be summarized. The number and percentage of antibiotics taken will be presented along with number of patients for Part I. Use of immunoglobulin replacement therapy over time will be summarized.

    Time frame: Part I: Baseline to Day 85 Part II: through study completion, an average of 1 year

  10. Part I and II: Pediatric Quality of Life Inventory (PedsQLTM) Parent Report for Children Questionnaire 4.0 Generic Core Scales

    To assess the ability of leniolisib to modify health related quality of life in pediatric patients with APDS. The unabbreviated scale title is SCALING AND SCORING OF THE PedsQL. The minimum and maximum values; are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. Higher scores indicate better HRQOL.

    Time frame: Part I: Baseline, Day 29, 57, & 85 Part II: through study completion, an average of 1 year

07

Study locations

7 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2023 (actual). Primary completion is estimated for Nov 2026, 45 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2022
First posted
Jun 30, 2022
StartActual
Feb 1, 2023
Primary completionEst.
Nov 30, 2026
CompletionEst.
Dec 30, 2026
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05438407
Collaborators
CMIC Co, Ltd. Japan, Labcorp Central Laboratory, Fortrea, Aixial Group
Responsible party
Sponsor
First posted
Jun 30, 2022
Start date
Feb 1, 2023
Primary completion
Nov 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
May 6, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Leniolisib

Start the discussion